Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,519.63
(
-1.10%
)
US TECH 100
23,179.20
(
-1.42%
)
Dow Jones
46,077.89
(
-0.76%
)
Brent Oil
102.99
(
4.26%
)
Bitcoin
68,826.12
(
-3.48%
)
News Focus
News Focus
Post# of 257293
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122813
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: urche post# 5708

Wednesday, 04/13/2005 10:34:04 AM

Wednesday, April 13, 2005 10:34:04 AM

Post# of 257293
Re: Xinlay meta analysis in prostate cancer:

On ABT’s CC yesterday, the company was asked (again) why the FDA would consider approving this NDA. The non-answer answer: the Agency accepted the application for filing.

Perhaps I should construct an iHub survey to ask which drug with a shaky data package has a better chance of approval: Xinlay or Retaane. I could even add Erbitux in H&N cancer to the mix.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today